BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $13.00 price target
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- BioCryst Pharmaceuticals, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/BCRX/price-target/">NASDAQ: BCRX</a>) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- BioCryst Pharmaceuticals, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/BCRX/price-target/">NASDAQ: BCRX</a>) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- BioCryst Pharmaceuticals, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/BCRX/price-target/">NASDAQ: BCRX</a>) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.MarketBeat
- BioCryst Pharmaceuticals, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/BCRX/price-target/">NASDAQ: BCRX</a>) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $10.00 MarketBeat
- BioCryst to Present at Upcoming Investor ConferencesGlobeNewswire
BCRX
Earnings
- 5/5/22 - Miss
BCRX
Sec Filings
- 5/9/22 - Form 10-Q
- 5/5/22 - Form 8-K
- 4/25/22 - Form DEFA14A
- BCRX's page on the SEC website